Zhejiang Hisun Pharmaceutical Co., Ltd., commonly known as Hisun Pharm, is a major player in the Chinese pharmaceutical industry. Founded in 1956 and headquartered in Taizhou, Zhejiang province, Hisun has grown to become one of the largest producers of antibiotics and anti-tumor drugs in China[1]. Let's dive into a comprehensive analysis of Hisun's market position, strengths, and strategic insights.
Company Overview
Hisun Pharmaceutical is a comprehensive pharmaceutical enterprise that integrates research, production, and marketing across multiple regions. The company entered the pharmaceutical field in the early 1970s and has since developed a robust business model over more than 60 years[1].
Key Financial Metrics
As of 2021, Hisun Pharmaceutical boasts:
- Total assets of 20 billion yuan
- Sales exceeding 10 billion yuan (RMB)[1]
These figures underscore Hisun's significant presence in the pharmaceutical market.
Product Portfolio and Therapeutic Areas
Hisun's product portfolio is diverse and covers several critical therapeutic areas:
- Anti-tumor drugs
- Anti-infective drugs
- Cardiovascular medications
- Endocrine treatments
- Immunosuppression drugs
- Antidepressants
- Orthopedic treatments[1]
The company's focus on these areas has allowed it to establish a strong foothold in the Chinese pharmaceutical market.
Market Share and Sales Performance
Hisun has achieved impressive market share in key segments:
In terms of market share, we are in the top tier of companies for anti-infective drugs and anti-tumor drugs, with 20 products and 100 million yuan in sales for each product.[1]
This performance demonstrates Hisun's competitive strength in these crucial therapeutic areas.
Research and Development Capabilities
Hisun Pharmaceutical places a strong emphasis on research and development, which is evident from its infrastructure and achievements:
R&D Infrastructure
- Central Research Institute
- State-level technology center
- Post-Doctoral Research Center
- Provincial academy fellow workstation[1]
R&D Approach and Achievements
Hisun employs a two-pronged approach to R&D:
- Independent research and development
- Cooperative research and development[1]
This strategy has yielded impressive results:
- 47 national key projects on new drug R&D
- 2 second-class prizes of the state technological invention award
- 9 scientific and technological progress awards at provincial or ministerial level
- Over 1,000 patent applications with more than 300 granted
- 5 Chinese patent excellence awards
- 1 Zhejiang patent excellence award[1]
These achievements highlight Hisun's commitment to innovation and its ability to translate research into marketable products.
Global Presence and Export Performance
Hisun has established a strong international presence:
- 80% of the company's API income comes from overseas markets
- APIs are exported to more than 70 countries and regions worldwide[1]
This global reach demonstrates Hisun's competitiveness in the international pharmaceutical market and its ability to meet global quality standards.
Strategic Partnerships and Joint Ventures
Hisun has engaged in strategic partnerships to enhance its market position and capabilities:
Hisun-Pfizer Joint Venture
In 2012, Hisun formed a joint venture with Pfizer, named Hisun-Pfizer Pharmaceuticals Co., Ltd. This partnership aims to:
- Develop, manufacture, and commercialize off-patent pharmaceutical products in China and global markets
- Leverage Hisun's product portfolio and market outreach
- Benefit from Pfizer's R&D, manufacturing quality management, and international market promotion capabilities[3]
The joint venture represents a significant step in Hisun's transition from an API manufacturer to an established branded generics company.
Manufacturing Capabilities
Hisun operates a globally integrated network of manufacturing facilities:
- 4 manufacturing facilities
- Capability to manufacture and deliver a wide range of finished products to more than 60 countries[2]
These state-of-the-art facilities enable Hisun to maintain high-quality standards and meet global demand.
Market Position in Specific Segments
Antibody-Drug Conjugates (ADCs)
Hisun has made strides in the emerging field of antibody-drug conjugates:
- Developed anti-HER ADC drug
- Collaboration with MabPlex for services ranging from toxin selection to manufacturing and IND application[6]
This focus on ADCs positions Hisun at the forefront of this innovative therapeutic approach.
Financial Performance and Market Valuation
As of February 14, 2025, Hisun's financial metrics and market valuation stand as follows:
- Market capitalization: 9.72 billion yuan
- P/E Ratio: -508.1x (compared to sector average of -9.3x)
- Price to Book Ratio: 1.2x (compared to sector average of 2.6x)
- Price to LTM Sales: 1.1x (compared to sector average of 3.6x)[5]
These figures suggest that while Hisun is a significant player in the market, there may be challenges in terms of profitability and valuation compared to sector averages.
Future Outlook and Strategic Direction
Hisun's future strategy focuses on:
- Expanding from upstream to downstream API and drug formulations
- Entering the big health industry business
- Expanding into the domestic market for special medicine and health foods[1]
The company's mission statement, "Perseverance in drug innovation, achieving the dream of health and longevity," underscores its commitment to innovation and global health[1].
Competitive Advantages
Hisun's competitive advantages include:
- Strong R&D capabilities and innovation track record
- Diverse product portfolio covering multiple therapeutic areas
- Significant global presence, especially in API exports
- Strategic partnerships with global pharmaceutical leaders
- Integrated manufacturing and research facilities
Challenges and Areas for Improvement
Despite its strengths, Hisun faces some challenges:
- Negative P/E ratio, indicating potential profitability issues
- Lower Price to Book and Price to Sales ratios compared to sector averages, suggesting potential undervaluation or efficiency concerns
- Intense competition in the Chinese pharmaceutical market, especially in generics and biosimilars
Key Takeaways
- Hisun Pharmaceutical is a major player in the Chinese pharmaceutical industry, with a strong focus on antibiotics and anti-tumor drugs.
- The company has robust R&D capabilities, evidenced by numerous patents and awards.
- Hisun has a significant global presence, with 80% of API income from overseas markets.
- Strategic partnerships, such as the Hisun-Pfizer joint venture, enhance the company's market position.
- While Hisun has strong market share in key segments, financial metrics suggest some challenges in profitability and valuation.
- The company's future strategy focuses on expanding its product range and entering new market segments.
FAQs
-
Q: What are Hisun Pharmaceutical's main therapeutic areas?
A: Hisun focuses on anti-tumor, anti-infective, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedic treatments.
-
Q: How significant is Hisun's international presence?
A: Very significant. 80% of Hisun's API income comes from overseas markets, and its APIs are exported to more than 70 countries.
-
Q: What is the Hisun-Pfizer joint venture?
A: It's a partnership formed in 2012 to develop, manufacture, and commercialize off-patent pharmaceutical products in China and global markets.
-
Q: How does Hisun's R&D capability compare to other Chinese pharmaceutical companies?
A: Hisun has strong R&D capabilities, evidenced by 47 national key projects, numerous awards, and over 300 granted patents.
-
Q: What are the main challenges facing Hisun Pharmaceutical?
A: Key challenges include potential profitability issues (indicated by a negative P/E ratio), lower valuation ratios compared to sector averages, and intense competition in the Chinese pharmaceutical market.
Sources cited:
[1] https://www.hisunpharm.com/en/
[2] https://www.hisunusa.com
[3] https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_hisun_announce_launch_of_hisun_pfizer_pharmaceuticals_co_ltd
[5] https://www.investing.com/equities/hisun-pharm
[6] https://www.pharmexec.com/view/antibody-drug-conjugates-china
Last updated: 2025-02-14
